| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 6.4 | 59.8 | Mixed | Healthy (excl pregnant) | Serum |
| Assessment of biological variation and analytic impreciion of CA 125, CEA and TPA in relation to monitoring of ovarian cancer, Tuxen MK, Solétormos G, Pertersen PH, Cioler V, Dombernovsky P, 1999, Gynecologic Oncology, 74, 12-22 | 12.6 | 58.3 | Females | Healthy (excl pregnant) | Serum |
| Biological variation and reference change vàlues of CA 19-9, CEA, AFP in sèrum of healthy individuals, Erden G, Barazi AO, Tezcan G and Yildirimkaya MM, 2008, Scand J Clin Lab Invest, 68, 212-8 | 30.87 | 37.14 | Mixed | Healthy (excl pregnant) | Serum |
| Interpretation of sequential measurements of cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer, Tuxen MK, Sölétormos G, Petersen PH and Dombernowsky P, 2001, Clin Chem Lab Med, 39, 531-8 | 17.3 | | Females | Healthy (excl pregnant) | Serum |
| Biological variation of tumor markers and its aplication in the detection of disease progression in patients with non-samll cell lung cancer, Trapé J, Perez de Olaguer J, Buxó J and López L, 2005, Clin Chem, 51, 219-22 | 9.9 | 35.6 | Males | Non-healthy (excl pregnant) | Serum |
| . Biological variations of seven tumor markers, Qi Z, Zhang Lin, Chen Y, Ma X et al, 2015, Clin Chim Acta, 450, 233-6 | 10.95 | 46.74 | Mixed | Healthy (excl pregnant) | Serum |
| Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation, Plebani M, Giacomini A, Beghi L, De Paoli M, Roveroni G, Galleotti F, Corsini A, Fraser CG, 1996, Anticancer Res, 16, 2249-52 | 10.9 | 178.0 | Males | Non-healthy (excl pregnant) | Serum |
| Interpretation of results for tumor markers on the basis of analytical imprecision an biological variation, Sölétormos G, Schioler V, Nielsen D, Skovsgaard T, Domnerbowsky P, 1993, Clin Chem, 39, 2077-83 | 9.3 | 86.8 | Females | Healthy (excl pregnant) | Serum |
| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 6.8 | 50.1 | Mixed | Healthy (excl pregnant) | Serum |
| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 6.4 | 62.9 | Mixed | Healthy (excl pregnant) | Serum |
| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 6.7 | 45.5 | Males | Healthy (excl pregnant) | Serum |
| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 6.6 | 67.8 | Females | Healthy (excl pregnant) | Serum |
| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 6.7 | 67.0 | Females | Healthy (excl pregnant) | Serum |
| Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation, Plebani M, Giacomini A, Beghi L, De Paoli M, Roveroni G, Galleotti F, Corsini A, Fraser CG, 1996, Anticancer Res, 16, 2249-52 | 10.9 | 178.0 | Mixed | Non-healthy (excl pregnant) | Serum |
| Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study, Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, | 7.2 | 41.2 | Females | Healthy (excl pregnant) | Serum |
| Witin-subject biological variation in disease: the case of tumour markers, Dittadi R, Peloso L and Gion M, 2008, Ann Clin Biochem, 45, 226-8 | 8.4 | | Mixed | Healthy (excl pregnant) | Unknown |
| Witin-subject biological variation in disease: the case of tumour markers, Dittadi R, Peloso L and Gion M, 2008, Ann Clin Biochem, 45, 226-8 | 19.3 | | Mixed | Healthy (excl pregnant) | Unknown |
